CLCN3, chloride voltage-gated channel 3, 1182

N. diseases: 67; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2931822
Disease: Nasopharyngeal carcinoma
Nasopharyngeal carcinoma
0.400 Biomarker disease BEFREE We previously reported that AQP-3 aquaglyceroporin and ClC-3 chloride channels could form complexes to regulate cell volume in nasopharyngeal carcinoma cells. 26794461 2016
CUI: C0007194
Disease: Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy
0.010 Biomarker disease BEFREE We also provide Clcn3 as a direct target of miR-1-3p which sheds light on the mechanism of HCM. 29885652 2018
CUI: C0017638
Disease: Glioma
Glioma
0.340 Biomarker disease CTD_human Transcripts for ClC-2 thru ClC-7 were detected in a human glioma cell line by PCR, whereas only ClC-2, ClC-3, and ClC-5 protein could be identified by Western blot. 12843258 2003
CUI: C0017638
Disease: Glioma
Glioma
0.340 AlteredExpression disease LHGDN Transcripts for ClC-2 thru ClC-7 were detected in a human glioma cell line by PCR, whereas only ClC-2, ClC-3, and ClC-5 protein could be identified by Western blot. 12843258 2003
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE Together, our data suggest that upregulation of ClC-3 by IGF-1 contributes to cell proliferation and tumor growth in breast cancer, and ClC-3 deficiency suppresses cell proliferation and tumor growth via the IGF/IGF receptor/ERK pathway. 29963105 2018
CUI: C0456909
Disease: Blindness
Blindness
0.010 Biomarker phenotype BEFREE Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion. 12059962 2002
CUI: C0424605
Disease: Developmental delay (disorder)
Developmental delay (disorder)
0.010 Biomarker phenotype BEFREE Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion. 12059962 2002
CUI: C0557874
Disease: Global developmental delay
Global developmental delay
0.010 Biomarker disease BEFREE Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion. 12059962 2002
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.050 Biomarker disease BEFREE To assess the roles of CLCN3 in breast cancer, we next performed three-dimensional (3D) spheroid proliferation analyses using MCF10A-ErbB2 cells treated with MCF10A-neo-derived exosomes or CLCN3 shRNA stably expressing SKBR3 and MDA-MB-453 breast cancer cells. 31608175 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.050 Biomarker disease BEFREE To assess the roles of CLCN3 in breast cancer, we next performed three-dimensional (3D) spheroid proliferation analyses using MCF10A-ErbB2 cells treated with MCF10A-neo-derived exosomes or CLCN3 shRNA stably expressing SKBR3 and MDA-MB-453 breast cancer cells. 31608175 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.010 Biomarker disease BEFREE This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure. 21602838 2011
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.010 Biomarker disease BEFREE This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure. 21602838 2011
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.010 Biomarker group BEFREE This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure. 21602838 2011
CUI: C0027877
Disease: Neuronal Ceroid-Lipofuscinoses
Neuronal Ceroid-Lipofuscinoses
0.210 Biomarker disease MGD These results indicated that the neurodegeneration observed in the Clcn3-/- mice was caused by an abnormality in the machinery which degrades the cellular protein and was associated with the phenotype of neuronal ceroid lipofuscinosis (NCL). 12059962 2002
CUI: C0027877
Disease: Neuronal Ceroid-Lipofuscinoses
Neuronal Ceroid-Lipofuscinoses
0.210 Biomarker disease BEFREE These results indicated that the neurodegeneration observed in the Clcn3-/- mice was caused by an abnormality in the machinery which degrades the cellular protein and was associated with the phenotype of neuronal ceroid lipofuscinosis (NCL). 12059962 2002
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.320 Biomarker disease BEFREE These findings indicate the vital role of CLC-3 in gastric cancer progression and its potential role of a therapeutic target for treatment. 29795988 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.020 Biomarker disease BEFREE These findings indicate the vital role of CLC-3 in gastric cancer progression and its potential role of a therapeutic target for treatment. 29795988 2018
CUI: C0376618
Disease: Endotoxemia
Endotoxemia
0.010 Biomarker phenotype BEFREE Therefore, the regulation of intestinal tissue integrity by ClC-3 is crucial for maintaining LPS-induced survival in mice with endotoxemia. 29972266 2018
CUI: C0017638
Disease: Glioma
Glioma
0.340 Biomarker disease BEFREE Therefore, the present study explored the involvement of CLCN3 in cisplatin resistance in human glioma U251 cells. 29963152 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.020 Biomarker phenotype BEFREE Therefore, cytoplasmic ClC-3 plays an active and key role in tumor metastasis and may be a valuable prognostic biomarker and a therapeutic target to prevent tumor spread. 25537517 2015
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.010 Biomarker group BEFREE Therefore, cytoplasmic ClC-3 plays an active and key role in tumor metastasis and may be a valuable prognostic biomarker and a therapeutic target to prevent tumor spread. 25537517 2015
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.060 Biomarker phenotype BEFREE The purpose of this study was to evaluate whether ClC-3 influences the migration and invasion of cervical squamous cell carcinoma cells and its possible mechanisms. 30905432 2019
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.320 Biomarker disease BEFREE The molecular mechanisms by which CLC-3 is regulated in GC are unclear. 30217218 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.020 Biomarker disease BEFREE The molecular mechanisms by which CLC-3 is regulated in GC are unclear. 30217218 2018
CUI: C3714636
Disease: Pneumonitis
Pneumonitis
0.010 GeneticVariation disease BEFREE The liver and lung inflammations in mice with ClC-3 deletion were significantly less than those in wild-type mice, and the levels of TNF-α and MIP-2 in serum were lower than those of wild-type mice. 29972266 2018